[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-334429-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-334429-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","identification-and-verification-of-ptpn3-as-a-novel-biomarker-in-predicting-cancer-prognosis-immunity-and-immunotherapeutic-efficacy","Identification and verification of PTPN3 - as a novel biomarker in predicting cancer prognosis, immunity, and immunotherapeutic efficacy","","Protein tyrosine phosphatase non-receptor type 3 (PTPN3) has attracted attention for regulating multiple tumor cell behaviors across cancer progression, yet its involvement in drug sensitivity, immunotherapy performance, tumor immune microenvironment, and patient prognosis remains insufficiently defined. RNA-seq from TCGA was used to assess PTPN3 across 33 cancer types, supported by immunohistochemistry in clinical cohorts and multi-database analyses for alterations, immune infiltration, TMB/MSI links, and pathway enrichment. The study further evaluated associations with PD-1/PD-L1 inhibitor outcomes and other therapeutic efficacy. Results show abnormal PTPN3 expression in multiple malignancies with strong prognostic relevance and correlations with immune cell infiltration, immune-related molecules, TMB/MSI, and responses to immunotherapy.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/identification-and-verification-of-ptpn3-as-a-novel-biomarker-in-predicting-cancer-prognosis-immunity-and-immunotherapeutic-efficacy/334429/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/identification-and-verification-of-ptpn3-as-a-novel-biomarker-in-predicting-cancer-prognosis-immunity-and-immunotherapeutic-efficacy/334429.png","ImageObject",300,407,{"name":42,"@type":43},"Jiven","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-07","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main goal of this study on PTPN3?","Question",{"text":63,"@type":64},"To identify and validate PTPN3 as a novel biomarker for predicting cancer prognosis, immune features, and immunotherapeutic effectiveness.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did the researchers measure PTPN3 in cancers?",{"text":68,"@type":64},"They analyzed TCGA RNA-seq data across 33 cancer types and used immunohistochemistry to validate PTPN3 expression in clinical cohorts.",{"name":70,"@type":61,"acceptedAnswer":71},"What relationships were found between PTPN3 and the tumor immune microenvironment?",{"text":72,"@type":64},"PTPN3 expression correlated with infiltration of multiple immune cell types and with many immune-related biomolecules, alongside associations with TMB and MSI.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},334429,1790623941,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","Zhou et al. European Journal  \nEuropean Journal of Medical Research (2024) 29:12  \n[https://doi.org/10.1186/s40001-023-01587-5](https://doi.org/10.1186/s40001-023-01587-5 of Medical Research)[ of Medical Research](https://doi.org/10.1186/s40001-023-01587-5 of Medical Research)  \n RESEARCH Open Access  \nIdentification and verification of PTPN3  \nas a novel biomarker in predicting cancer prognosis, immunity, and immunotherapeutic efficacy  \nZiting Zhou1†, Zhengjun Lin1†, Mingrui Wang1,5, Lifan Wang1, Yuqiao Ji1, Jing Yang1, Yaocheng Yang1, Guanghui Zhu2,3,4* and Tang Liu 1*  \nAbstract  \nBackground The importance of protein tyrosine phosphatase non-receptor type 3 (PTPN3) in controlling multifaceted tumor cell behaviors throughout cancer development has received widespread attention. Nevertheless, little is known about the biological roles of PTPN3 in drug sensitivity, immunotherapeutic effectiveness, tumor immune microenvironment, and cancer prognosis.  \nMethods The Cancer Genome Atlas (TCGA) database’s RNAseq data were used to examine the expression of PTPN3 in 33 different cancer types. In addition, immunohistochemistry (IHC) was performed to validate the expression of PTPN3 across various cancer types within our clinical cohorts. The features of PTPN3 alterations were demonstrated throughout the cBioPortal database. This study focused on examining the prognostic and clinicopathological importance of PTPN3 through the acquisition of clinical data from theTCGA database. The investigation of PTPN3’s probable role in the tumor immune microenvironment was demonstrated by the application of CIBERSORT, ESTIMATE algorithms, and theTISIDB database. Using Spearman’s rank correlation coefficient, the relationships between PTPN3 expression and tumor mutation burden (TMB) and microsatellite instability (MSI) were evaluated. To further investigate the putative biological activities and downstream pathways of PTPN3 in various cancers in humans, Gene Set Enrichment Analysis (GSEA) was carried out. In addition, an examination was conducted to explore the associations between PTPN3 and the effectiveness of PD-1/PD-L1 inhibitors, utilizing data extracted from the GEO database.  \nResults PTPN3 was abnormally expressed in multiple cancer types and was also strictly associated with the prognosis of cancer patients. IHC was used to investigate and confirm the various expression levels of PTPN3 in various malignancies, including breast cancer, lung cancer, sarcoma, and kidney renal clear cell carcinoma in our clinical cohorts. There is a high correlation between the levels of PTPN3 expression in different cancers and infiltrating  \n†Ziting Zhou and Zhengjun Lin have contributed equally to this work and share the first authorship.  \n*Correspondence: Guanghui Zhu [zgh5650@163.com](zgh5650@163.com)[ ](zgh5650@163.com)Tang Liu [liutang1204@csu.edu.cn](liutang1204@csu.edu.cn)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ()[. The Creative Commons Public Domain Dedication w","cbCainIMo0Nwyzzf","https://ap.wps.com/l/cbCainIMo0Nwyzzf","pdf",17992854,21,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions","[{\"question\":\"What was the main goal of this study on PTPN3?\",\"answer\":\"To identify and validate PTPN3 as a novel biomarker for predicting cancer prognosis, immune features, and immunotherapeutic effectiveness.\"},{\"question\":\"How did the researchers measure PTPN3 in cancers?\",\"answer\":\"They analyzed TCGA RNA-seq data across 33 cancer types and used immunohistochemistry to validate PTPN3 expression in clinical cohorts.\"},{\"question\":\"What relationships were found between PTPN3 and the tumor immune microenvironment?\",\"answer\":\"PTPN3 expression correlated with infiltration of multiple immune cell types and with many immune-related biomolecules, alongside associations with TMB and MSI.\"}]","Identification and verification of PTPN3 - as a novel biomarker in predicting cancer prognosis, immunity, and immunotherapeutic efficacy | PDF",1790006607,53]